Glycoprotein News and Research

RSS

Studying influenza A virus and peptide interactions with electrically controllable DNA nanoconstructs

German scientists used DNA nanolevers to target the interaction between a peptide known as PeB and influenza A.

3 Nov 2021

Humoral immunity following heterologous and homologous COVID-19 vaccination regimens

Researchers sought to analyze immune responses after homologous vaccinations or after heterologous Vector/mRNA vaccinations, with respect to anti-COVID-19 immune responses and the development of autoantibodies.

3 Nov 2021

SARS-CoV-2 neutralizing antibodies discovered in a 20-year-old human antibody library

In an article published in the open-access journal Advance Engineering, a multinational team of researchers reported the selection and characterization of 3 potent SARS-CoV-2 antibodies - S-E6, S-B8, and S-D4 - from a pre-COVID-19 human combinatorial antibody library that was established 20 years ago.

3 Nov 2021

Isolation of potent neutralizing monoclonal antibodies using nanoparticles displaying SARS-CoV-2 S glycoprotein

A new study aimed to identify several potent neutralizing RBD-directed and NTD-directed mAbs that used a nanoparticle displaying the S glycoprotein to capture SARS-CoV-2-specific B cells.

2 Nov 2021

Emerging SARS-CoV-2 variant A.30 efficiently evades vaccine-induced immunity

A recent study published in the journal Cellular & Molecular Immunology shows that a new A.30 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can evade vaccine-induced antibodies and might spread outside the lungs extraordinarily well, with important implications for our public health response.

1 Nov 2021

Structure of human-infecting canine coronavirus HuPn-2018 spike glycoprotein

As CCoV-HuPn-2018 has been recently isolated in a child's respiratory swab, researchers from the University Of Washington have been examining the structure of the virus.

28 Oct 2021

A high-throughput pipeline for identifying nanobodies that target and neutralize SARS-CoV-2

Researchers in the United States have developed a cost-effective, high-throughput pipeline for identifying effective nanobodies that target and neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

26 Oct 2021

Hyperimmune antibody produced in horses may be an efficient approach to combat covid-19

A study conducted by a consortium of Brazilian researchers has demonstrated that a hyperimmune serum consisting of purified antibody fragments produced in horses may be an efficient approach to combat covid-19.

26 Oct 2021

Study suggests seropositive individuals produce anti-SARS-CoV-2 antibodies with improved potency and breadth

Researchers isolated single cells among individuals with and without prior infection with the SARS-CoV-2 vaccinated with BNT162b2 mRNA vaccine and compared the nature of the neutralizing antibody response against the original Wuhan virus and the subsequent variants.

25 Oct 2021

The neutralization potential of nanobodies against SARS-CoV-2

A recent review describes the role of nanobodies as a new class of recombinant antibodies that are used in the treatment of COVID-19.

20 Oct 2021

Safety and oral immunogenicity of a VSV-derived mucosal vaccine against SARS-CoV-2

A team of researchers exploited the known tropism of vesicular stomatitis virus to develop an oral vaccine that expresses the immunogenic SARS-CoV-2 spike glycoprotein in the oral mucosa.

20 Oct 2021

Research may provide clues to how viral infections contribute to neurodegeneration

Some viral diseases could possibly contribute to neurodegeneration. DZNE researchers report this in the scientific journal "Nature Communications".

19 Oct 2021

Does vitamin D deficiency increase the risk of SARS-CoV-2 infections?

A recent study posted to the medRxiv* preprint server attempted to understand the relationship between vitamin D levels and COVID-19 by studying a population of UK healthcare workers who exhibited symptoms for COVID-19.

17 Oct 2021

Serologic testing algorithm to detect disparities in SARS-CoV-2 infection prevalence and vaccination uptake

A new study recently published on the medRxiv* preprint server demonstrates the use of a serological testing algorithm for identifying disparities in infection rates and vaccine uptake amongst the study population to enable public health interventions.

17 Oct 2021

Fibrin immunotherapy may resolve blood clotting induced by SARS-CoV-2

A group of researchers from the United States discovered that the spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can induce the formation of highly inflammatory blood clots amenable to neutralization by a fibrin-targeting monoclonal antibody – opening the door for a completely new strategy to reduce thrombotic inflammation in coronavirus disease 2019 (COVID-19).

17 Oct 2021

Chilblain-like lesions and COVID-19

The ongoing COVID-19 pandemic brought about by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has also been responsible for various cutaneous manifestations. Among them, chilblain-like lesions (CLL) have been found to occur more frequently.

7 Oct 2021

Graphene biosensor in a portable and wireless device for rapid SARS-CoV-2 detection

A new study posted to the medRxiv* server and led by Dr. Mattia D'Agostino, Dr. Eleonora Pavoni and Dr. Alice Romagnoli from the Polytechnic University of Marche in Ancona (Italy), a gFET biosensor that uses angiotensin-converting enzyme 2 (ACE2) as a bioreceptor has been put forth as a viable solution.

6 Oct 2021

University of Washington partners with USAID to better identify and prevent future pandemics

Randy CarnellLaboratory medicine scientists look through the window of equipment used in analyzing virus samples.

6 Oct 2021

Study looks at immunosuppressants and COVID vaccine efficacy

Researchers investigate the effects of five established immunosuppressant medications following COVID-19 vaccination.

4 Oct 2021

Immune response to SARS-CoV-2 variants of concern after natural infection or vaccination

A recent review paper published in the MDPI's journal Viruses highlights how available vaccines may be effective in protecting individuals against severe forms of coronavirus disease 2019 (COVID-19), but the protection against infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its transmission to others may be reduced – with consequences for community protection and herd immunity.

3 Oct 2021

Glycoprotein News and Research

Studying influenza A virus and peptide interactions with electrically controllable DNA nanoconstructs

Humoral immunity following heterologous and homologous COVID-19 vaccination regimens

SARS-CoV-2 neutralizing antibodies discovered in a 20-year-old human antibody library

Isolation of potent neutralizing monoclonal antibodies using nanoparticles displaying SARS-CoV-2 S glycoprotein

Emerging SARS-CoV-2 variant A.30 efficiently evades vaccine-induced immunity

Structure of human-infecting canine coronavirus HuPn-2018 spike glycoprotein

A high-throughput pipeline for identifying nanobodies that target and neutralize SARS-CoV-2

Hyperimmune antibody produced in horses may be an efficient approach to combat covid-19

Study suggests seropositive individuals produce anti-SARS-CoV-2 antibodies with improved potency and breadth

The neutralization potential of nanobodies against SARS-CoV-2

Safety and oral immunogenicity of a VSV-derived mucosal vaccine against SARS-CoV-2

Research may provide clues to how viral infections contribute to neurodegeneration

Does vitamin D deficiency increase the risk of SARS-CoV-2 infections?

Serologic testing algorithm to detect disparities in SARS-CoV-2 infection prevalence and vaccination uptake

Fibrin immunotherapy may resolve blood clotting induced by SARS-CoV-2

Chilblain-like lesions and COVID-19

Graphene biosensor in a portable and wireless device for rapid SARS-CoV-2 detection

University of Washington partners with USAID to better identify and prevent future pandemics

Study looks at immunosuppressants and COVID vaccine efficacy

Immune response to SARS-CoV-2 variants of concern after natural infection or vaccination

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News